Date of Award


Degree Type

Selective Evidence-Based Medicine Review

Degree Name

Master of Science in Health Sciences - Physician Assistant


Physician Assistant Studies

Department Chair

John Cavenagh, MBA, PhD, PA-C


OBJECTIVE: The objective of this selective EBM review is to determine whether or not Flibanserin is a safe and effective treatment to increase sexual desire in premenopausal women with Hypoactive Sexual Desire Disorder.

STUDY DESIGN: Review of three randomized controlled trials published in 2013, 2012, and 2012; selection was based on their relevance to the clinical question and if they contained patient oriented outcomes.

DATA SOURCES: Three peer-reviewed randomized controlled trials comparing the use of Flibanserin to placebo in the treatment of Hypoactive Sexual Desire Disorder were found on PubMed.

OUTCOME(S) MEASURED: For each trial patients were divided into two groups and assigned to either Flibanserin treatment or placebo treatment. Each trial assessed number of satisfying sexual events (SSE), Patient Global Impression of Improvement (PGI-I), and Adverse Events (AEs), events leading to the discontinuation of the trial.

RESULTS: All three trials showed a statistically significant (p

CONCLUSIONS: Based on all three trials, there is a statistically significant increase in sexual desire with the use of Flibanserin compared to the use of placebo in premenopausal women with HSDD. The analysis of PGI-I showed a moderately low NNT indicating that the drug, Flibanserin, was effective in improving the women’s condition. The analysis of AEs showed a moderate numbers needed to harm indicating that there are risks to taking Flibanserin. All serious safety concerns were investigated and deemed not related to the use of Flibanserin. Flibanserin is a relatively safe drug, and is an effective treatment of HSDD symptoms in premenopausal women.